Scholarlink

<p>Allogeneic stem cell transplantation (SCT) is a curative treatment in myelodysplastic syndromes (MDS). We performed a retrospective single center study of all patients with newly diagnosed higher risk (HR) MDS (IPSS-R &gt; 3.5 points) between 2000 and 2023. We identified 2045 patients with HR-MDS, of which 427 (21%) underwent SCT. The median post-SCT overall survival (OS) was 23.9 months, progression-free survival (PFS) was 14.4 months, 5-year cumulative incidence (CI) of relapse was 37%, and 5-year CI of treatment-related mortality (TRM) was 25%. There were no significant differences in OS, PFS, CI of relapse, or CI of TRM between age categories. Survival improved over the observation period (median 11.8 months in 2000–2010, 28.2 months in 2011–2016, and 40.2 months in 2017–2023; <i>p</i> = 0.01). By multivariate analysis, <i>TP53</i> status was the most important predictor of post-SCT OS. Patients with <i>TP53</i>-wild type MDS had an OS of 69% at 5 years (HR for death 0.32 with SCT, <i>p</i> &lt; 0.001). Patients with <i>TP53</i> mutations had poor outcomes, with OS of 9.1 months in monoallelic (HR for death 0.88 with SCT, <i>p</i> = 0.69) and 6.8 months in biallelic (HR for death 0.76 with SCT, <i>p</i> = 0.14). SCT can lead to excellent long-term survival in <i>TP53</i>-wild type HR MDS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月27日

查看全文
  • Alexandre Bazinet,
  • Alex Bataller,
  • Kelly Chien,
  • Koji Sasaki,
  • Guillermo Montalban-Bravo,
  • Danielle Hammond,
  • Ian Bouligny,
  • Mahesh Swaminathan,
  • Wei Ying Jen,
  • Eitan Kugler,
  • Rashmi Kanagal-Shamanna,
  • Tapan Kadia,
  • Gautam Borthakur,
  • Courtney DiNardo,
  • Nicholas Short,
  • Naveen Pemmaraju,
  • Elias Jabbour,
  • Naval Daver,
  • Farhad Ravandi,
  • Samuel Urrutia,
  • Georgina Gener-Ricos,
  • Julie Braish,
  • Robert Briski,
  • Juan Jose Rodriguez-Sevilla,
  • Ziyi Li,
  • Richard E. Champlin,
  • Elizabeth J. Shpall,
  • Amin Alousi,
  • Betul Oran,
  • Chitra Hosing,
  • Jeremy L. Ramdial,
  • Amanda Olson,
  • Sherry Pierce,
  • Julianne Chen,
  • Hagop Kantarjian,
  • Guillermo Garcia-Manero,
  • Uday Popat

摘要

Allogeneic stem cell transplantation (SCT) is a curative treatment in myelodysplastic syndromes (MDS). We performed a retrospective single center study of all patients with newly diagnosed higher risk (HR) MDS (IPSS-R > 3.5 points) between 2000 and 2023. We identified 2045 patients with HR-MDS, of which 427 (21%) underwent SCT. The median post-SCT overall survival (OS) was 23.9 months, progression-free survival (PFS) was 14.4 months, 5-year cumulative incidence (CI) of relapse was 37%, and 5-year CI of treatment-related mortality (TRM) was 25%. There were no significant differences in OS, PFS, CI of relapse, or CI of TRM between age categories. Survival improved over the observation period (median 11.8 months in 2000–2010, 28.2 months in 2011–2016, and 40.2 months in 2017–2023; p = 0.01). By multivariate analysis, TP53 status was the most important predictor of post-SCT OS. Patients with TP53-wild type MDS had an OS of 69% at 5 years (HR for death 0.32 with SCT, p < 0.001). Patients with TP53 mutations had poor outcomes, with OS of 9.1 months in monoallelic (HR for death 0.88 with SCT, p = 0.69) and 6.8 months in biallelic (HR for death 0.76 with SCT, p = 0.14). SCT can lead to excellent long-term survival in TP53-wild type HR MDS.